Every 8-K that CV SCIENCES INC (CVSI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CVSI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVSI filings page.
CV Sciences, Inc. reported second quarter 2026 revenue of $3.0 million, down 17.5% from $3.6 million a year earlier, with a gross margin of 48.6%. The company generated an operating loss of $0.3 million and a net loss of $0.8 million for the quarter.
Operating expenses fell 11.3% to $1.7 million, contributing to positive operating cash flow of $0.1 million for the first six months of 2026. Cash was $0.3 million at June 30, 2026, while total liabilities were $5.0 million and stockholders’ equity was $1.6 million. Adjusted EBITDA was a loss of $0.1 million for the quarter. Management highlighted growth in the +PlusHLTH™ and new product portfolio, which accounted for 44% of net revenue since January 1, 2023.
CV Sciences, Inc. reported results from its 2026 annual stockholder meeting held virtually on June 2, 2026. There were 193,458,420 shares of common stock outstanding as of the April 6, 2026 record date, and 116,234,784 shares, or about 60.1%, were represented by proxy, establishing a quorum.
Stockholders elected three directors to serve until the next annual meeting: Dr. Jamie Corroon, Joseph Dowling, and Bill McCorkle. A proposal to authorize the board to implement a reverse stock split at a ratio between 1-for-10 and 1-for-800 any time before May 30, 2029 was not approved. Stockholders also ratified the selection of Haskell & White LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
CV Sciences, Inc. reported first quarter 2026 results showing lower sales but improved cost control. Revenue was $3.2 million, down from $3.6 million a year earlier and $3.3 million in the fourth quarter 2025, mainly from lower volumes amid restrictive regulations. Gross margin improved to 48.9% from 46.0% a year ago. Operating expenses (excluding a prior-year payroll tax reversal) fell 13.3% to $1.9 million, and the company posted an operating loss of $0.3 million and a net loss of $0.6 million.
Adjusted EBITDA loss narrowed to about $0.1 million from $0.3 million a year earlier, reflecting tighter expense management. Cash was $0.3 million at March 31, 2026, slightly higher than year-end. Management highlighted a completed debt restructuring to strengthen the balance sheet and noted that products launched since January 2023 contributed 43% of net revenue, supported by 45 new product launches.
CV Sciences, Inc. entered into an April 9, 2026 amendment with its institutional investor to modify existing secured convertible notes and a newly issued senior secured convertible note. The amendment lowers the fixed conversion price of the amended notes from $0.06 per share to $0.03 per share.
On April 6, 2026, the company issued a Third Note with a principal amount of $99,614.04, which may be converted into common stock. The Third Note’s conversion price is set at $0.03 per share, based on the lesser of that level and the $0.04 closing price before its original issuance date. The Third Note’s maturity was extended to July 6, 2027.
CV Sciences, Inc. reported 2025 revenue of $13.8 million, down from $15.7 million in 2024, but improved profitability metrics. Gross margin rose to 49.0% from 45.6%, and operating loss narrowed to $0.5 million from $2.2 million, with net loss reduced to $0.96 million.
In the fourth quarter, revenue was $3.3 million, slightly above the prior quarter, and the company generated positive adjusted EBITDA of about $0.1 million after a full-year adjusted EBITDA loss of $0.3 million. Management cut operating expenses 17.2% to $7.7 million and attributes the revenue decline mainly to temporary product outages and regulatory headwinds.
Cash ended 2025 at $0.3 million with total assets of $7.0 million and total liabilities of $5.5 million. The company highlights 39 new products since 2023, with 39% of 2025 net revenue from these launches, plus new +PlusCBD and +PlusHLTH offerings and a completed debt restructuring in early 2026 aimed at strengthening its financial position.
CV Sciences, Inc. entered into an agreement with its institutional investor to amend and restate two secured promissory notes into senior secured convertible notes. The Amended Notes now carry a fixed conversion price of $0.06 per share and are initially convertible into 37,600,000 shares of common stock.
The notes’ outstanding principal was increased by 20%, giving an aggregate principal of $2,256,000, and the company eliminated its prior obligation to make monthly redemptions before maturity. A beneficial ownership cap limits the investor to 4.99% of outstanding shares, optionally rising to 9.99% with notice.
A true-up feature aims to ensure the investor’s net sale proceeds equal the principal converted; if the aggregate shortfall across both notes exceeds $94,000, the company will issue a new senior secured convertible note, potentially due April 6, 2027, with no stated cap on shares from that note. The securities were issued without registration under the Securities Act, in reliance on Section 4(a)(2) and/or Regulation D.
CV Sciences, Inc. furnished an 8‑K announcing it issued a press release covering financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference into Item 2.02 via Item 7.01.
The release includes non‑GAAP financial measures with GAAP reconciliations and related explanations. The information is furnished, not filed, and includes forward‑looking statements that are subject to risks and uncertainties.
CV Sciences, Inc. entered into a new note purchase agreement with an institutional investor and issued a secured promissory note with an original principal amount of $600,000. After a $150,000 original issuance discount, a $150,000 payment tied to modifying a prior purchase agreement, and $13,125 of legal and other fees, the Company received net proceeds of $300,000.
The Note is secured by all of the Company’s assets and the assets and intellectual property of its subsidiaries under a Security Agreement and an Intellectual Property Security Agreement dated October 6, 2025. Monthly repayments of $46,153.85 begin on April 6, 2026, with all unpaid amounts due by April 6, 2027, and an 8% discount applies if the Note is fully repaid within six months of closing.
The Note includes customary events of default. On certain events of default, the investor may increase the outstanding balance by 20% or 5%, declare all amounts immediately due, and begin charging interest on the outstanding balance at up to 18% per annum or the maximum rate allowed by law.
CV Sciences, Inc. entered into an agreement with an institutional investor to amend its existing secured promissory note originally issued for a principal amount of $1,600,000.
The amendment extends the note’s maturity to February 12, 2027, revises the monthly principal redemptions to $106,666.67 for the first three months, then zero principal for six months, followed by $106,666.67 for the next twelve months, in each case plus any accrued but unpaid interest. As part of the revised terms, the company also agreed to pay the investor an additional $150,000 in cash, while all other provisions of the original note and purchase agreement remain in effect.